PT2694116T - Nanopartículas à base de lípidos - Google Patents

Nanopartículas à base de lípidos

Info

Publication number
PT2694116T
PT2694116T PT12767275T PT12767275T PT2694116T PT 2694116 T PT2694116 T PT 2694116T PT 12767275 T PT12767275 T PT 12767275T PT 12767275 T PT12767275 T PT 12767275T PT 2694116 T PT2694116 T PT 2694116T
Authority
PT
Portugal
Prior art keywords
lipid
based nanoparticles
nanoparticles
Prior art date
Application number
PT12767275T
Other languages
English (en)
Portuguese (pt)
Inventor
Annapragada Ananth
L Eriksen Jason
A Tanifum Eric
Dasgupta Indrani
c cook Stephen
Original Assignee
Univ Texas
Alzeca Biosciences Llc
Board Of Regents Of The Univ Of Houston System
Texas Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2694116(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Alzeca Biosciences Llc, Board Of Regents Of The Univ Of Houston System, Texas Childrens Hospital filed Critical Univ Texas
Publication of PT2694116T publication Critical patent/PT2694116T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PT12767275T 2011-04-06 2012-04-06 Nanopartículas à base de lípidos PT2694116T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06

Publications (1)

Publication Number Publication Date
PT2694116T true PT2694116T (pt) 2018-10-12

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12767275T PT2694116T (pt) 2011-04-06 2012-04-06 Nanopartículas à base de lípidos

Country Status (14)

Country Link
US (1) US9801957B2 (enExample)
EP (2) EP2694116B1 (enExample)
JP (3) JP6212032B2 (enExample)
KR (2) KR101973063B1 (enExample)
CN (1) CN104144708B (enExample)
AU (3) AU2012239888B9 (enExample)
BR (1) BR112013025633A2 (enExample)
CA (1) CA2831480C (enExample)
DK (1) DK2694116T3 (enExample)
ES (1) ES2685824T3 (enExample)
MX (1) MX357227B (enExample)
PL (1) PL2694116T3 (enExample)
PT (1) PT2694116T (enExample)
WO (1) WO2012139080A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801957B2 (en) * 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
EP3542828A1 (en) * 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
PL3458074T3 (pl) * 2016-05-16 2024-11-12 Board Of Regents Of The University Of Texas System KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
EP3548002B1 (en) 2016-11-30 2025-04-30 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
JP7545393B2 (ja) * 2019-01-24 2024-09-04 アルゼカ バイオサイエンシズ、エルエルシー 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
KR102546470B1 (ko) * 2020-01-29 2023-06-21 텍사스 칠드런스 하스피탈 아밀로이드 침착의 mri용 표적 조영제
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
WO2021163585A1 (en) 2020-02-12 2021-08-19 Texas Children's Hospital Targeted contrast agents for mri of alpha-synuclein deposition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
AU2003217950A1 (en) 2002-03-05 2003-09-22 Cleveland State University Agglomerated particles for aerosol drug delivery
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7803351B2 (en) * 2004-08-20 2010-09-28 Washington University Blood brain barrier permeation peptides
WO2006032705A2 (en) * 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
EP1888034A2 (en) * 2005-05-26 2008-02-20 Yissum Research Development Company, of The Hebrew University of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2008054498A2 (en) * 2006-04-07 2008-05-08 The Board Of Trustees Of The University Of Illinois Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
CA2695204A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
CA2708028A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) * 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JP2012520898A (ja) 2009-03-19 2012-09-10 マーヴァル バイオサイエンシーズ，インコーポレイテッド 画像化におけるコントラスト強調のための組成物および方法
US9334304B2 (en) * 2009-04-02 2016-05-10 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
AU2012223210B2 (en) 2011-03-02 2016-12-22 Board Of Regents Of The University Of Texas System Vesicle compositions
US9801957B2 (en) * 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes

Also Published As

Publication number Publication date
JP2019151664A (ja) 2019-09-12
DK2694116T3 (en) 2018-09-03
AU2012239888B9 (en) 2017-10-12
US20120258044A1 (en) 2012-10-11
JP6212032B2 (ja) 2017-10-18
AU2012239888A2 (en) 2014-05-08
MX2013011231A (es) 2015-03-05
AU2017232156C1 (en) 2019-10-24
AU2019246775A1 (en) 2019-10-31
PL2694116T3 (pl) 2018-12-31
AU2017232156B2 (en) 2019-07-11
EP3366313A1 (en) 2018-08-29
JP6533813B2 (ja) 2019-06-19
HK1203827A1 (en) 2015-11-06
KR101973063B1 (ko) 2019-04-30
CA2831480C (en) 2020-09-29
CN104144708A (zh) 2014-11-12
WO2012139080A3 (en) 2014-05-01
KR102035187B1 (ko) 2019-11-08
JP2014523854A (ja) 2014-09-18
KR20140074868A (ko) 2014-06-18
MX357227B (es) 2018-07-02
ES2685824T3 (es) 2018-10-11
EP2694116B1 (en) 2018-06-13
CA2831480A1 (en) 2012-10-11
CN104144708B (zh) 2017-07-28
AU2012239888A1 (en) 2013-11-07
AU2012239888B2 (en) 2017-06-22
KR20190031334A (ko) 2019-03-25
EP2694116A2 (en) 2014-02-12
EP2694116A4 (en) 2015-06-03
BR112013025633A2 (pt) 2017-08-08
US9801957B2 (en) 2017-10-31
JP2018035167A (ja) 2018-03-08
WO2012139080A2 (en) 2012-10-11
AU2017232156A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
DK3424953T3 (en) Terapeutiske antistoffer
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
EP2723631A4 (en) QUADFOILER
EP2662268A4 (en) CAP MOUNTING STRUCTURE
EP2776444A4 (en) dihydropteridinones
PL2694116T3 (pl) Nanocząstki na bazie lipidów
AP2014007621A0 (en) 2-Thiopyrimidinones
DK2770906T3 (en) Applanationstonometer
SG11201402471SA (en) Photocatalyst-supporting structure
GB201101727D0 (en) Obuoy
GB201100001D0 (en) TidySqueeze2
AU5031P (en) BESYS Beschorneria yuccoides
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU5026P (en) Goldstrike Agapanthus inapertus
GB201102529D0 (en) Fine B-Day
GB201109229D0 (en) New uses
AP00723S1 (en) Autorickshaw
GB201102635D0 (en) Panalock
GB201103804D0 (en) T-zee spotdrive
GB201102833D0 (en) Evac-sack
GB201102667D0 (en) Coolbreeze
GB201101675D0 (en) i-mc
AU338110S (en) Barstool
GB201100364D0 (en) Aimspray